NASDAQ:OBSVObseva Stock Price, Forecast & News

$4.32

-0.10 (-2.26 %)

(As of 06/2/2020 11:44 AM ET)

Add

Compare

Today's Range

$4.20

Now: $4.32▼

$4.40

50-Day Range

$2.01

MA: $3.04▼

$4.35

52-Week Range

$1.63

Now: $4.32▼

$12.97

Volume8,412 shs

Average Volume893,766 shs

Market Capitalization$209.82 million

P/E RatioN/A

Dividend YieldN/A

Beta1.03

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Obseva has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.25, Obseva has a potential upside of 415.0% from its current price of $4.32.
Amount of Analyst Coverage
Obseva has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Obseva has received 286 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Obseva has received 334 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Obseva has received 53.87% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote “Outperform” if you believe OBSV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Obseva does not currently pay a dividend.
Dividend Growth
Obseva does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Obseva insiders have not sold or bought any company stock.
Percentage Held by Institutions
53.03% of the stock of Obseva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Obseva are expected to grow in the coming year, from ($1.69) to ($1.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Obseva is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Obseva is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Obseva has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OBSV

Previous Symbol

CUSIPN/A

CIK1685316

Webwww.obseva.com

Phone41-22-552-3840

Debt

Debt-to-Equity Ratio0.69

Current Ratio2.87

Quick Ratio2.87

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.01 per share

Price / Book4.28

Profitability

EPS (Most Recent Fiscal Year)($2.49)

Net Income$-108,790,000.00

Net MarginsN/A

Return on Equity-167.15%

Return on Assets-91.89%

Miscellaneous

Employees43

Outstanding Shares48,570,000

Market Cap$209.82 million

Next Earnings Date8/5/2020 (Estimated)

OptionableNot Optionable

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

Obseva (NASDAQ:OBSV) Frequently Asked Questions

How has Obseva's stock been impacted by COVID-19 (Coronavirus)?

Obseva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OBSV stock has increased by 68.1% and is now trading at $4.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Obseva?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Obseva.

When is Obseva's next earnings date?

Obseva is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Obseva.

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) announced its earnings results on Tuesday, May, 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.00. View Obseva's earnings history.

What price target have analysts set for OBSV?

4 analysts have issued 12-month target prices for Obseva's stock. Their forecasts range from $4.00 to $36.00. On average, they anticipate Obseva's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 415.0% from the stock's current price. View analysts' price targets for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:

1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (5/29/2020)
2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)

Has Obseva been receiving favorable news coverage?

Press coverage about OBSV stock has trended very positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Obseva earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutObseva.

Are investors shorting Obseva?

Obseva saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 718,500 shares, a decrease of 35.8% from the April 30th total of 1,120,000 shares. Based on an average daily trading volume, of 579,000 shares, the short-interest ratio is currently 1.2 days. Currently, 2.5% of the company's shares are short sold. View Obseva's Current Options Chain.

Who are some of Obseva's key competitors?

Some companies that are related to Obseva include Akero Therapeutics (AKRO), Eagle Pharmaceuticals (EGRX), Kadmon (KDMN), Molecular Templates (MTEM), Dynavax Technologies (DVAX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), G1 Therapeutics (GTHX), Provention Bio (PRVB), ZIOPHARM Oncology (ZIOP), Homology Medicines (FIXX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Ardelyx (ARDX) and Morphic (MORF). View all competitors.

What other stocks do shareholders of Obseva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obseva investors own include Gilead Sciences (GILD), Allena Pharmaceuticals (ALNA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Zosano Pharma (ZSAN), Corbus Pharmaceuticals (CRBP) and SCYNEXIS (SCYX).

Who are Obseva's key executives?

Obseva's management team includes the following people:

Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
Mr. Mario Vincent Corso, Sr. Director of Investor Relations
Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

Who are Obseva's major shareholders?

Obseva's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rock Springs Capital Management LP (2.88%), Zurcher Kantonalbank Zurich Cantonalbank (0.32%), Deutsche Bank AG (0.23%), Two Sigma Investments LP (0.12%), Two Sigma Advisers LP (0.06%) and Spark Investment Management LLC (0.04%).

Which institutional investors are buying Obseva stock?

OBSV stock was acquired by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Deutsche Bank AG, Zurcher Kantonalbank Zurich Cantonalbank, Two Sigma Investments LP, Two Sigma Advisers LP, Spark Investment Management LLC, and BlackRock Inc..

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $4.32.

How big of a company is Obseva?

Obseva has a market capitalization of $209.82 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Obseva employs 43 workers across the globe.

What is Obseva's official website?

The official website for Obseva is www.obseva.com.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff